Last updated: September 8, 2026
Pneumococcal 13-valent conjugate vaccine, marketed primarily as Prevnar 13 by Pfizer, remains a major commercial vaccine but is in structural decline in high-income markets. Its revenue base is being displaced by higher-valency products, especially Pfizer’s Prevnar 20, Merck’s Vaxneuvance and Capvaxive, and government immunization-policy changes. The product retains value in pediatric programs, emerging markets, public tenders and countries that have not fully transitioned to newer vaccines.
Pfizer reported Prevnar-family revenue of approximately $6.4 billion in 2023. That figure includes Prevnar 13 and newer Prevnar products and does not isolate PCV13 revenue. The key financial issue is therefore product-family migration rather than an abrupt loss of the franchise. [1]
What is pneumococcal 13-valent conjugate vaccine?
Pneumococcal 13-valent conjugate vaccine contains capsular polysaccharides from 13 Streptococcus pneumoniae serotypes conjugated to a nontoxic diphtheria CRM197 carrier protein. The formulation is designed to generate an immune response in infants, young children and adults.
Prevnar 13 was developed by Wyeth and became part of Pfizer’s portfolio following Pfizer’s acquisition of Wyeth in 2009. The U.S. Food and Drug Administration approved Prevnar 13 for infants and young children in February 2010 and later expanded its use to adults aged 50 and older. [2]
Product profile
| Attribute |
Prevnar 13 |
| Active technology |
13 pneumococcal polysaccharides conjugated to CRM197 |
| Sponsor |
Pfizer |
| U.S. product name |
Prevnar 13 |
| FDA approval |
2010 pediatric approval |
| Biological product |
Conjugate vaccine |
| Primary markets |
United States, Europe and international public-health markets |
| Main competitors |
Prevnar 20, Vaxneuvance, Capvaxive, Synflorix |
| Commercial status |
Mature product under displacement by higher-valency vaccines |
When does Prevnar 13 lose exclusivity?
Prevnar 13 has passed the period of practical market exclusivity associated with its original approval. The BPCIA’s 12-year reference-product exclusivity period for a biologic approved in 2010 would have ended in 2022, subject to statutory interpretation of the product’s first licensure date and any relevant regulatory complications. [3]
That date does not create automatic competitive entry. Vaccines are not interchangeable with ordinary small-molecule generics, and PCV13 is difficult to reproduce because its commercial value depends on serotype-specific polysaccharide production, conjugation chemistry, analytical controls, immunogenicity data and manufacturing consistency.
The product’s effective protection has therefore depended more on manufacturing scale, regulatory approvals, procurement contracts, brand recognition and Pfizer’s integrated vaccine platform than on a single unexpired composition patent.
Patent and regulatory protection
Publicly available product-level patent information is less useful for PCV13 than for an oral small-molecule drug. Relevant protection can include:
- Serotype-specific polysaccharide preparation.
- CRM197 conjugation methods.
- Carrier-protein and linker chemistry.
- Formulation and adjuvant systems.
- Manufacturing controls and purification processes.
- Combination-vaccine applications.
- Device and packaging claims.
The original composition and technology patents are unlikely to block all competitors indefinitely. The larger barrier is the cumulative manufacturing and clinical package. A rival must demonstrate acceptable safety, immunogenicity, serotype coverage and production reliability.
What is the FDA regulatory status of Prevnar 13?
Prevnar 13 remains a licensed biologic vaccine, but its strategic position in the U.S. adult market has weakened sharply. The Centers for Disease Control and Prevention now recommends higher-valency pneumococcal vaccines for many adult populations, including PCV20 or PCV21 alone, or PCV15 followed by PPSV23 in specified circumstances. [4]
For children, the CDC recommends either PCV15 or PCV20 for routine vaccination. PCV13 remains relevant where product availability, procurement rules or local policy supports its use, but it is no longer the default growth product in the U.S. pediatric market. [5]
Orange Book and Purple Book status
Prevnar 13 is a biologic licensed under a biologics license application. The Orange Book is primarily used for approved small-molecule drugs and does not function as the principal patent-listing database for biologics.
The FDA’s Purple Book is the relevant reference for licensed biological products and biosimilar or interchangeable products. The absence of a conventional Orange Book patent listing should not be interpreted as the absence of intellectual-property protection.
How many products compete with Prevnar 13?
The competitive field has shifted from one dominant PCV13 product to a higher-valency market.
| Product |
Sponsor |
Valency |
Market position |
| Prevnar 13 |
Pfizer |
13 |
Mature, declining |
| Vaxneuvance |
Merck |
15 |
Pediatric and adult competitor |
| Prevnar 20 |
Pfizer |
20 |
Pfizer’s principal replacement product |
| Capvaxive |
Merck |
21 |
Adult-focused higher-valency entrant |
| Synflorix |
GSK |
10 |
International and pediatric presence |
| Pneumovax 23 |
Merck |
23 |
Polysaccharide vaccine, not a conjugate equivalent |
The competitive comparison is not based solely on valency. Serotype epidemiology, pediatric efficacy, adult immunogenicity, national schedules, procurement price and evidence for invasive pneumococcal disease all affect product selection.
How does Prevnar 13 compare with Prevnar 20?
Prevnar 20 is the principal successor to Prevnar 13 within Pfizer’s portfolio. It adds seven serotypes and offers broader coverage than PCV13. The commercial strategy is substitution: Pfizer can migrate patients, physicians, health systems and public purchasers to a higher-valency product while retaining the Prevnar franchise.
| Factor |
Prevnar 13 |
Prevnar 20 |
| Serotypes |
13 |
20 |
| Commercial maturity |
Mature |
Growth and replacement product |
| Pediatric role |
Reduced in the U.S. |
Increasingly preferred where recommended |
| Adult role |
Declining |
Principal Pfizer adult product |
| Pricing power |
Under pressure |
Stronger while protected as newer technology |
| Revenue outlook |
Decline or stabilization at lower base |
Growth, subject to competition |
Prevnar 20 received FDA approval for adults in 2021 and expanded pediatric approval in 2024. [6] The pediatric indication is particularly important because routine childhood vaccination creates recurring, population-scale demand.
What is the financial trajectory of the Prevnar franchise?
Pfizer’s reported Prevnar-family revenue has remained in the multibillion-dollar range, but the composition of that revenue is changing.
| Year |
Pfizer Prevnar-family revenue |
Interpretation |
| 2021 |
Approximately $5.9 billion |
Strong franchise before full higher-valency transition |
| 2022 |
Approximately $6.3 billion |
Continued demand and product expansion |
| 2023 |
Approximately $6.4 billion |
Family-level resilience, with newer products contributing |
| 2024 onward |
Product-level trajectory diverges |
Prevnar 13 declines while Prevnar 20 absorbs demand |
Sources report the franchise rather than a clean Prevnar 13-only figure. Pfizer’s filings group Prevnar products, which limits direct measurement of PCV13 revenue erosion. [1]
Revenue drivers
The franchise has five major revenue drivers:
- Pediatric birth cohorts create recurring demand and reduce dependence on adult booster campaigns.
- Government procurement determines large portions of volume outside the private U.S. market.
- Higher-valency products support premium pricing and product migration.
- Adult recommendations can rapidly shift demand between PCV13, PCV15, PCV20 and PCV21.
- International vaccination coverage remains below levels in the United States and Western Europe, creating long-term volume opportunity.
Revenue risks
PCV13 revenue faces several direct risks:
- Replacement by PCV20 in adult and pediatric schedules.
- Merck’s Vaxneuvance and Capvaxive competing for public and private contracts.
- Tender-driven price compression in emerging markets.
- Lower adult use after the CDC moved away from routine PCV13 use for many adults.
- Inventory reductions as national programs transition products.
- Manufacturing capacity being reallocated toward newer vaccines.
What patent litigation affects Prevnar 13?
No broad, generic-style Paragraph IV litigation cycle defines the U.S. PCV13 market. That reflects the regulatory structure of vaccines and the complexity of demonstrating a substitutable conjugate product.
A competitor could challenge patents through district-court litigation, inter partes review or other post-grant procedures. In practice, the commercial threat is more likely to arise from an independently developed, separately licensed vaccine than from an automatic generic launch.
The principal legal risk is therefore patent and regulatory competition around next-generation PCVs, not a conventional tablet-generic event. Pfizer’s more material defensive position comes from product know-how, clinical data, manufacturing capacity and market access.
Are there biosimilar risks for pneumococcal 13-valent vaccine?
Biosimilar risk is limited in the near term. A biosimilar or interchangeable designation is technically possible for a complex biologic, but conjugate vaccines present unusual comparability problems.
A competitor would need to address:
- Identity and purity of each polysaccharide.
- Degree and site of conjugation to CRM197.
- Molecular size and aggregation.
- Serotype-specific immune responses.
- Stability across the product’s shelf life.
- Manufacturing consistency across multiple antigens.
- Clinical and postmarketing safety requirements.
The greater threat is a new multivalent conjugate vaccine, not a biosimilar version of PCV13. Higher-valency products also make direct PCV13 replication less attractive commercially.
What manufacturing and intellectual-property barriers protect the product?
The manufacturing process is a material barrier even where patent protection has weakened. PCV13 requires the coordinated production of 13 bacterial polysaccharide antigens, purification of each antigen, activation and conjugation to CRM197, formulation, filling and lot-release testing.
Manufacturing barriers include:
- Specialized fermentation and purification infrastructure.
- Validated conjugation processes.
- Serotype-specific analytical assays.
- High-volume sterile filling capacity.
- Cold-chain distribution.
- Regulatory comparability data.
- Supplier qualification for complex biological inputs.
These barriers support continued commercial value for Pfizer in lower-income and tender markets, where the company’s scale can matter more than premium pricing.
Which companies are challenging Pfizer in the pneumococcal vaccine market?
Merck is Pfizer’s principal global competitor in higher-valency conjugate vaccines. Vaxneuvance competes in pediatric and adult indications, while Capvaxive targets additional adult serotypes and was approved by the FDA in 2024. [7]
GSK’s Synflorix remains relevant in international pediatric markets, although its 10-valent coverage limits direct comparability with PCV13, PCV15 and PCV20.
The market is likely to divide into three segments:
- Higher-income adult markets dominated by PCV20 and PCV21.
- Pediatric markets where national schedules determine PCV15, PCV20 or legacy PCV13 use.
- International tender markets where price, supply reliability and World Health Organization policy influence product selection.
What generic launch scenarios exist for PCV13?
A conventional generic launch scenario is unlikely. The realistic scenarios are:
| Scenario |
Probability profile |
Commercial effect |
| Direct biosimilar-style PCV13 |
Low near-term |
Could pressure price if approved and interchangeable |
| Independent PCV13-like vaccine |
Moderate technical possibility |
Requires major clinical and manufacturing investment |
| PCV15 or PCV20 replacement |
High |
Accelerates legacy PCV13 decline |
| Tender-driven substitution |
High in price-sensitive markets |
Reduces volume or net price |
| Continued PCV13 use in selected markets |
High |
Extends tail revenue |
What licensing deals support the product?
Prevnar 13 is principally a Pfizer-owned franchise following the Wyeth acquisition. Pfizer’s public filings identify the product as part of its internal Prevnar portfolio rather than a major current royalty-bearing external license. [1]
The acquisition itself remains commercially important because it transferred the product, manufacturing platform and related pneumococcal vaccine capabilities into Pfizer’s global vaccine business. No major new licensing transaction is required for the current PCV13-to-PCV20 migration strategy.
How strong is the Prevnar 13 patent estate?
The patent estate is commercially moderate rather than absolute. The original product has reached maturity, and the strongest protection now comes from cumulative know-how, regulatory history, manufacturing scale and portfolio substitution.
| Protection category |
Relative strength |
| Original product exclusivity |
Low to moderate |
| Manufacturing know-how |
High |
| Clinical and regulatory package |
High |
| Brand and physician familiarity |
Moderate |
| Pediatric procurement access |
High where contracts remain |
| Adult market protection |
Low after higher-valency recommendations |
| Direct biosimilar deterrence |
Moderate to high |
Key Takeaways
- Prevnar 13 is a mature biologic vaccine under replacement, not immediate abandonment.
- Pfizer’s Prevnar-family revenue was approximately $6.4 billion in 2023, but reported figures combine PCV13 with newer products.
- Prevnar 20 is the main successor and is absorbing demand from PCV13.
- Merck’s Vaxneuvance and Capvaxive increase competitive pressure.
- Adult U.S. demand has shifted toward higher-valency products following CDC recommendations.
- Pediatric use remains commercially relevant, but PCV15 and PCV20 have stronger strategic positioning.
- Patent expiry is less important than manufacturing complexity, clinical evidence and procurement access.
- Conventional generic entry is unlikely; independent higher-valency competition is the more credible threat.
- PCV13 revenue should decline in developed markets while retaining a longer commercial tail in international and tender-driven markets.
FAQs
Is Prevnar 13 still used in children?
Yes. Prevnar 13 remains licensed and may be used in markets or programs that have not transitioned to PCV15 or PCV20. Its U.S. strategic position has weakened as newer vaccines gain preference.
Is Prevnar 13 interchangeable with Prevnar 20?
They are not automatically interchangeable in every setting. Product selection depends on CDC guidance, patient history, age, risk factors and jurisdiction-specific recommendations.
Does Prevnar 13 have a biosimilar competitor?
No widely established biosimilar or interchangeable PCV13 competitor has displaced Prevnar 13 in the U.S. market. Competition is primarily from independently developed higher-valency conjugate vaccines.
Why does CRM197 matter in PCV13 manufacturing?
CRM197 is the carrier protein that links pneumococcal polysaccharides to create a stronger immune response. The conjugation process affects product quality, immunogenicity and manufacturing comparability.
What is the long-term investment thesis for PCV13?
PCV13 has a declining standalone outlook but remains part of a valuable Pfizer pneumococcal franchise. The financial thesis depends on Pfizer’s ability to convert PCV13 demand into Prevnar 20 demand while preserving pediatric and international volume.
References
- Pfizer Inc. (2024). 2023 annual report. Pfizer.
- U.S. Food and Drug Administration. (2010). FDA approves new pneumococcal vaccine for children. FDA.
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
- Centers for Disease Control and Prevention. (2024). Pneumococcal vaccine recommendations. CDC.
- Centers for Disease Control and Prevention. (2024). Child and adolescent immunization schedule by age. CDC.
- U.S. Food and Drug Administration. (2024). Prevnar 20 approval for pediatric use. FDA.
- U.S. Food and Drug Administration. (2024). FDA approves Capvaxive pneumococcal 21-valent conjugate vaccine. FDA.
